|Systematic (IUPAC) name|
|Mol. mass||384.469 g/mol|
JWH-200 is an analgesic drug from the aminoalkylindole family, which acts as a cannabinoid receptor agonist. Its binding affinity at the CB1 receptor is 42nM, around the same as that of THC, but interestingly its analgesic potency in vivo was higher than that of other analogues which had stronger CB1 binding affinity in vitro, around 3x that of THC but with less sedative effect, most likely reflecting favourable pharmacokinetic characteristics.
- ↑ Huffman JW, Padgett LW. Recent Developments in the Medicinal Chemistry of Cannabimimetic Indoles, Pyrroles and Indenes. Current Medicinal Chemistry, 2005; 12: 1395-1411.
- ↑ Bell MR, D'Ambra TE, Kumar V, et al (1991). Antinociceptive (aminoalkyl)indoles. Journal of Medicinal Chemistry. 34 (3): 1099–1110. PMID 1900533
- ↑ Compton DR, Gold LH, Ward SJ, Balster RL, Martin BR (1992). Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. Journal of Pharmacology and Experimental Therapeutics. 263 (3): 1118–26. PMID 1335057
|Plant cannabinoids||CBD • CBDV • CBN • CBG • CBV • CBL • THC • THC-C4 • THCV|
|Cannabinoid metabolites||11-Hydroxy-THC • 11-nor-9-Carboxy-THC|
|Endogenous cannabinoids||Arachidonoyl ethanolamide (Anandamide or AEA) • 2-Arachidonoylglycerol (2-AG) • 2-Arachidonyl glyceryl ether (noladin ether) • Virodhamine • N-arachidonoyl-dopamine (NADA)|
|Synthetic cannabinoid agonists|
|Endocannabinoid activity enhancers|
|Cannabinoid antagonists and inverse agonists|
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies